Canton Strategic Holdings, Inc. (formerly Tharimmune, Inc.) has undergone a fundamental strategic shift, prioritizing digital asset treasury management and investment in the Canton Network, moving away from its primary focus on biotechnology operations. The company raised approximately $545 million in gross proceeds through a November 2025 private placement offering, consisting of a cash offering and a cryptocurrency pre-funded warrants offering. An additional $54.9 million in gross proceeds was raised through an underwritten registered direct offering in January 2026. The company's liquidity has significantly strengthened, alleviating previously disclosed substantial doubt about its ability to continue as a going concern, with sufficient liquidity projected through at least March 2027. Net loss for the year ended December 31, 2025, increased to $35.9 million from $12.2 million in 2024, primarily due to a $22.0 million unrealized loss from digital asset holdings. Research and development expenses decreased by $3.3 million (52%) to $3.1 million in 2025, while general and administrative expenses increased by $11.0 million (182%) to $17.0 million, reflecting the strategic shift and increased personnel costs. The company holds 3,339,567,946 Canton Coin (CC) units with a fair value of $501,760,369 as of December 31, 2025, and recognized a deferred tax liability of $117,934,191 related to these holdings. Key management changes include the appointment of Mark Wendland as CEO and Chairman, Mark Toomey as President, and Jacob Asbury as CFO, effective November and December 2025, respectively. The biotechnology segment continues to develop therapeutic candidates, with GV104 (for synthetic opioid exposure prophylaxis) anticipating a rolling NDA submission in H1 2027 and FDA approval in H1 2028, and GV023 (oral anti-TNF-alpha antibody) licensed from Intract Pharma Limited.